The antiviral drug likely has a gradient of benefit, with those at highest risk most likely to see the greatest benefit, experts say in an editorial.
Among fully vaccinated, study shows Paxlovid does not shorten symptoms
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows